Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase

PHASE3CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

April 30, 2013

Study Completion Date

May 31, 2013

Conditions
Gaucher Disease
Interventions
DRUG

Taliglucerase alfa

Intravenous infusion every 2 weeks

Trial Locations (10)

10016

Neurogenetics, NYU at Rivergate, New York

30033

Department of Human Genetics, Emory University School of Medicine, Decatur

31096

Rambam Medical Center, Haifa

33065

University Research Foundation for Lysosomal Storage Diseases, Inc., Coral Springs

50009

Sala de Hematologia, Hospital Universitario Miguel Servet, Zaragoza

Unknown

Bone Marrow Transplant Service, The Royal Melbourne Hospital, Parkville

Shaare Zedek Medical Center, Jerusalem

Lysosomal Disorders Service, Addenbrookes Hospital NHS Trust, Cambridge

M5G 1X5

Mount Sinai Hospital, Toronto

NW3 2QG

Royal Free Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY